Symbol not found

:IMMU   00:00AM GMT
0.00
0.00 (0.00%)
Mergers / Acquisitions

Gilead Sciences Says To Acquire Immunomedics For $88 Per Share In Cash

Published: 09/13/2020 19:19 GMT
(IMMU) - To Acquire Immunomedics.
Entered Into a Definitive Agreement Pursuant to Which Gilead Will Acquire Immunomedics for $88.00 per Share in Cash.
Transaction is Anticipated to Close During Q4 of 2020.
Transaction Values Immunomedics at Approximately $21 Billion.
Will Acquire All Remaining Shares Not Tendered in Offer Through Second Step Merger at Same Price As Tender Offer.
Tender Offer is Not Subject to Financing Condition,will Be Funded Through About $15 Billion in Cash on Hand & About $6 Billion in Newly Issued Debt.
Acquisition of Immunomedics is Expected to Be Neutral to Accretive to Gilead's Non-GAAP EPS in 2023 and Significantly Accretive Thereafter.